Point Nemo Capital LLC Acquires 13,614 Shares of Halozyme Therapeutics, Inc. $HALO

Key Points

• Point Nemo Capital sharply increased its Halozyme stake in the third quarter, buying 13,614 shares and ending the period with 13,626 shares worth about $1.5 million. Institutional investors and hedge funds own 97.79% of the stock.
• Halozyme reported third-quarter revenue of $493 million, up 39% year over year, and adjusted EPS of $2.39, topping analyst estimates; the company also raised its 2026 guidance.
• Analysts’ consensus rating is Moderate Buy, with an average price target of $106.09. Insiders sold 125,852 shares worth about $13.5 million over the past 90 days.

Point Nemo Capital LLC increased its holdings in shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO - Free Report) by 113,450.0% during the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 13,626 shares of the biopharmaceutical company's stock after buying an additional 13,614 shares during the period. Point Nemo Capital LLC's holdings in Halozyme Therapeutics were worth $1,504,000 at the end of the most recent quarter.

Other hedge funds have also added to or reduced their stakes in the company. Ethic Inc. acquired a new position in Halozyme Therapeutics in the 3rd quarter valued at approximately $523,000. AlphaCentric Advisors LLC raised its stake in shares of Halozyme Therapeutics by 4.2% during the third quarter. AlphaCentric Advisors LLC now owns 9,821 shares of the biopharmaceutical company's stock valued at $1,084,000 after acquiring an additional 395 shares during the last quarter. Abacus Wealth Partners LLC lifted its holdings in shares of Halozyme Therapeutics by 5.1% during the third quarter. Abacus Wealth Partners LLC now owns 3,529 shares of the biopharmaceutical company's stock worth $390,000 after purchasing an additional 171 shares during the period. Heritage Family Offices LLP acquired a new position in shares of Halozyme Therapeutics during the third quarter worth $77,000. Finally, Kestra Advisory Services LLC lifted its holdings in shares of Halozyme Therapeutics by 47.9% during the third quarter. Kestra Advisory Services LLC now owns 14,793 shares of the biopharmaceutical company's stock worth $1,633,000 after purchasing an additional 4,788 shares during the period. 97.79% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

HALO has been the subject of a number of recent research reports. JPMorgan Chase & Co. increased their price objective on Halozyme Therapeutics from $78.00 to $79.00 and gave the company a "neutral" rating in a report on Tuesday, November 3rd. Citigroup reiterated a "market outperform" rating on shares of Halozyme Therapeutics in a research report on Friday, August 7th. Citizens Jmp increased their price target on Halozyme Therapeutics from $93.00 to $149.00 and gave the company a "market outperform" rating in a research note on Friday. Benchmark restated a "buy" rating on shares of Halozyme Therapeutics in a research report on Tuesday, July 21st. Finally, Zacks Research upgraded Halozyme Therapeutics from a "hold" rating to a "strong-buy" rating in a report on Tuesday, October 13th. One research analyst has rated the stock with a Strong Buy rating, nine have issued a Buy rating, two have given a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and a consensus price target of $106.09.

Insider Transactions at Halozyme Therapeutics

In related news, CEO Helen Torley sold 20,000 shares of the company's stock in a transaction dated Wednesday, September 9th. The stock was sold at an average price of $107.43, for a total transaction of $2,148,600.00. Following the sale, the chief executive officer owned 767,780 shares in the company, valued at $82,482,605.40. This represents a 2.54% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Bernadette Connaughton sold 1,626 shares of the firm's stock in a transaction that occurred on Monday, August 10th. The stock was sold at an average price of $102.80, for a total value of $167,152.80. Following the sale, the director directly owned 40,418 shares of the company's stock, valued at $4,154,970.40. This represents a 3.87% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last ninety days, insiders sold 125,852 shares of company stock valued at $13,538,046. Corporate insiders own 2.50% of the company's stock.

Halozyme Therapeutics News Summary

Here are the key news stories impacting Halozyme Therapeutics this week:

• Positive Sentiment: Q3 revenue rose 39% year over year to $493 million and adjusted EPS of $2.39 beat estimates. Record royalty revenue increased 44% to $341 million. Halozyme also raised its 2026 revenue, royalty, EBITDA and adjusted EPS guidance. Q3 results and guidance
• Positive Sentiment: The FDA approved Johnson & Johnson’s RYBREVANT FASPRO, which uses Halozyme’s ENHANZE technology, for certain patients with advanced head and neck cancer. The expanded use could support future royalties. FDA approval
• Positive Sentiment: Halozyme said its analysis of Medicare’s drug-price negotiation rule indicates zero to minimal impact on royalty revenue through at least 2035, easing a potential long-term concern. Medicare rule assessment
• Neutral Sentiment: Citizens JMP raised its price target to $149 and maintained an outperform rating, while Wells Fargo raised its target to $110 but kept an equal-weight rating—signaling differing views on further upside. Citizens JMP rating
• Negative Sentiment: Despite the earnings beat and higher guidance, reports noted a negative share reaction and questions around the guidance reset, suggesting results may not have met elevated investor expectations. The Merck patent dispute also remains an investor focus. Earnings reaction and guidance questions

Halozyme Therapeutics Price Performance

Shares of NASDAQ HALO opened at $103.63 on Friday. Halozyme Therapeutics, Inc. has a twelve month low of $61.22 and a twelve month high of $134.00. The firm has a fifty day simple moving average of $115.19 and a 200 day simple moving average of $84.73. The company has a market capitalization of $11.76 billion, a PE ratio of 26.37, a P/E/G ratio of 0.39 and a beta of 0.92. The company has a quick ratio of 2.31, a current ratio of 2.71 and a debt-to-equity ratio of 13.50.

Halozyme Therapeutics (NASDAQ:HALO - Get Free Report) last issued its quarterly earnings results on Thursday, November 5th. The biopharmaceutical company reported $2.39 EPS for the quarter, beating analysts' consensus estimates of $2.30 by $0.09. The business had revenue of $492.97 million for the quarter, compared to analysts' expectations of $491.63 million. Halozyme Therapeutics had a net margin of 26.93% and a return on equity of 488.26%. The business's quarterly revenue was up 39.1% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $1.72 earnings per share. On average, sell-side analysts forecast that Halozyme Therapeutics, Inc. will post 8.32 EPS for the current year.

About Halozyme Therapeutics

Halozyme Therapeutics, Inc is a biotechnology company focused on developing drug-delivery technologies and medicines. Its ENHANZE platform uses a recombinant human hyaluronidase enzyme, rHuPH20, to temporarily modify tissue under the skin and help enable the subcutaneous administration of certain biologic medicines that might otherwise require intravenous infusion.

Halozyme licenses ENHANZE to pharmaceutical and biotechnology partners, which use the technology in their own products. The company also markets Hylenex recombinant, a hyaluronidase product used to facilitate the dispersion and absorption of other injected medicines and fluids.

Founded in 1998 and based in San Diego, California, Halozyme serves patients in multiple countries through its own commercial activities and, particularly for ENHANZE-enabled medicines, through its licensing partners.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.